Bristol-Myers Squibb Company (BMY)
|52 Week Range||65.28-81.44|
|1y Target Est||-|
|DCF Unlevered||BMY DCF ->|
|DCF Levered||BMY LDCF ->|
|Debt / Equity||211.53%||Strong Buy|
Upgrades & Downgrades
Latest BMY news
4 Dividend Stocks To Buy In April 2023
31 March 2023
All 4 of these stocks are trading at a discount to their historical average. These companies have the ability to outperform regardless of the economic backdrop.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
29 March 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Bristol Myers (BMY) Gets Approval of Psoriasis Drug in EU
28 March 2023
Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?
28 March 2023
Big pharma stocks ought to perform well in the current high interest rate environment. Eli Lilly and Bristol Myers Squibb have long been top value plays.
Bristol-Myers Squibb: Nobody Panic! Share Price Stumble Shouldn't Last
27 March 2023
I expected Bristol-Myers Squibb Company stock to keep rising in value through 2023 and perhaps reach triple figures. Instead, the share price has fallen 5% this year as inflationary headwinds and drug...
10 Dividend Growth Stocks - March 2023
26 March 2023
This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I sort them in descending order by quality s...
Bristol-Myers Squibb: Growth Story And Valuation Is Convincing
26 March 2023
Despite dealing with a pharmaceutical company, Bristol-Myers Squibb's performance during recessions was mixed and the stock also performed horrible in the last two decades. For fiscal 2022, the compan...
Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?
22 March 2023
Investors have assigned a higher multiple to LLY stock due to its robust pipeline and better profitability, as discussed below If we look at stock returns, Eli Lilly, with 15% returns in the last twel...
These Are The Top 3 Large Caps For Yield And Dividend Growth
21 March 2023
Look no further if you want yield and distribution growth in a large-cap name with a blue-chip appeal. A simple screen using Marketbeat.com's dividend screener will turn up names like Comcast (NASDAQ:...
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >